Skip to content

uniQure QURE Enterprise value

Enterprise value at other companies

Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$1.83B-51.1%
Denali Therapeutics Inc. logo
Denali Therapeutics Inc.DNLI
$2.69B+37.1%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$5.2B+77.3%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
$4.93B+69.8%
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
$7.06B+44.2%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$16.77B+178%

Other financials

Income statement

See full
Revenue$3.6M+127%
Gross profit$3.3M+144%
Operating income-$45.7M-16.2%
Net income-$53.5M-22.7%
EPS (diluted)-$0.85-3.7%

Balance sheet

See full
Cash & equivalents$140.0M-35.6%
Total debt$63.3M-4.3%
Total equity$149.3M+343%
Total assets$778.7M+28.6%

Cash flow

See full
Operating cash flow-$38.2M+13.3%
CapEx$140.0K+11.1%
Free cash flow-$38.4M+13.2%

Valuation

See full
Market cap$3.09B+78.4%
P/S170.9×+85.1×

Profitability

See full
Gross margin90.6%-2.9pp
Operating margin-1,059.7%+380pp
Net margin-1,154.4%+89.3pp
FCF margin-953.7%+169pp

Returns & leverage

See full
Return on equity-228.2%-11.6pp
Debt / equity0.4×-1.5×
Current ratio10.4×-1.6×

Where this comes from

Calculated from uniQure’s reported figures.

The official record: uniQure’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about uniQure's enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is uniQure's enterprise value?
uniQure (QURE) reported enterprise value of $945.68M in Q1 2026.
How has uniQure's enterprise value changed year-over-year?
uniQure's enterprise value increased by 124.0% year-over-year, from $422.18M to $945.68M.
What is the long-term trend for uniQure's enterprise value?
Over 5 years (2020 to 2025), uniQure's enterprise value has grown at a -0.3% compound annual growth rate (CAGR), from $1.5B to $1.47B.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.